Get the Stockscreener App
0.95
1.69%
0.0158
After Hours:
.96
0.01
+1.05%
Palatin Technologies Inc. stock is traded at $0.95, with a volume of 224.27K.
It is up +1.69% in the last 24 hours and down -3.06% over the past month.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
See More
Previous Close:
$0.9342
Open:
$0.95
24h Volume:
224.27K
Relative Volume:
0.81
Market Cap:
$18.57M
Revenue:
$7.10M
Net Income/Loss:
$-31.59M
P/E Ratio:
-0.3711
EPS:
-2.56
Net Cash Flow:
$-26.75M
1W Performance:
-20.83%
1M Performance:
-3.06%
6M Performance:
-52.50%
1Y Performance:
-51.53%
1-Day Range:
$0.9051
$1.00
1-Week Range:
$0.9051
$1.26
52-Week Range:
$0.68
$5.65
Palatin Technologies Inc. Stock (PTN) Company Profile
Name
Palatin Technologies Inc.
Sector
Industry
Phone
609-495-2200
Address
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PTN | 0.95 | 18.57M | 7.10M | -31.59M | -26.75M | -2.56 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-15 | Reiterated | Canaccord Genuity | Buy |
| Jan-12-15 | Reiterated | ROTH Capital | Buy |
| May-23-12 | Initiated | Noble Financial | Buy |
| Jan-23-07 | Initiated | Next Generation | Buy |
Palatin Technologies Inc. Stock (PTN) Latest News
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Shifts Focus to Obesity Treatments - TipRanks
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - Nasdaq
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - BioSpace
Palatin Technologies Sets Q1 2025 Earnings Release for November 14 | PTN Stock News - StockTitan
Palatin Technologies (BUE:PTN) 9-Day RSI : N/A (As of Nov. 06, 2024) - GuruFocus.com
Palatin Technologies (BUE:PTN) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PR Newswire
HC Wainwright Reaffirms Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN) - Defense World
Finansavisen - Finansavisen
Palatin Receives Notice of Non-Compliance from NYSE American - GuruFocus.com
Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - Marketscreener.com
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - GuruFocus.com
PTNPalatin Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium - StockTitan
Palatin Presents Foundational Data on Novel and Highly Selective - GuruFocus.com
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium – Company AnnouncementFT.com - Financial Times
Dry Eye Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin faces NYSE American non-compliance notice By Investing.com - Investing.com Australia
Palatin faces NYSE American non-compliance notice - Investing.com
Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results - Defense World
Palatin Technologies, Inc. (AMEX:PTN) Q4 2024 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc. (PTN) is a good investment, but the stock may be undervalued - US Post News
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 By Investing.com - Investing.com South Africa
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 - Investing.com Canada
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... - Yahoo Finance
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - BioSpace
Palatin shares hold steady as analyst maintains buy rating and $17 target - Investing.com Canada
An Analysis of Palatin Technologies Inc. (PTN)’s Potential Price Growth - Knox Daily
PTN Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Stock Market Recap: Palatin Technologies Inc. (PTN) Concludes at 0.84, a -11.27 Surge/Decline - The Dwinnex
PTN underperforms with a -1.39 decrease in share price - US Post News
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - Marketscreener.com
Market Momentum: Palatin Technologies Inc. (PTN) Registers a -15.70 Decrease, Closing at 1.02 - The Dwinnex
Palatin Technologies (NYSEAMERICAN:PTN) Share Price Crosses Above 200-Day Moving Average of $0.00 - Defense World
Palatin Technologies stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Palatin Technologies stock hits 52-week low at $1.25 - Investing.com India
Planet Fitness (NYSE:PLNT) Sets New 12-Month High at $84.69 - MarketBeat
Palantir Technologies Inc [PLTR] Records 200-Day SMA of $23.71 - Knox Daily
Palantir Stock Hits 52-Week Highs Thursday: What's Going On? - Benzinga
Pharvaris initiated with a Buy at JonesResearch - TipRanks
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Palantir Stock Is Skyrocketing. 1 Analyst Thinks It Has Another 38% Gain Ahead. - MSN
Palantir Technologies (NYSE:PLTR) Shares Up 0.6% - MarketBeat
Priority Technology (NASDAQ:PRTH) Hits New 52-Week High at $6.90 - Defense World
PRTH stock soars to 52-week high, touches $6.87 amid growth - Investing.com
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Quest Partners LLC Purchases New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Palatin Technologies Inc. Stock (PTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):